Chang , which tackles cancer by altering immune cells to make them fight the disease better, has raised $ 288 m in an IPO on CAR . The firm is one of a number tackling cancer with chimeric antigen receptor ( CAR-T ) therapies. It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 61 other preclinical CAR-T products. The company has a license to use a gene editing technology from Cellectis (NASDAQ: CLLS, called TALEN, to help develop its cell therapies. It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies. CAR-T also wants to expand Allogene -T to more cancer types.
Chang , which tackles cancer by altering immune cells to make them fight the disease better, has raised $ 288 m in an IPO on CAR . The firm is one of a number tackling cancer with chimeric antigen receptor ( CAR-T ) therapies. It bought the US rights to the UCART19 cell therapy from Pfizer along with the rights to 61 other preclinical CAR-T products. It is engineering allogenic cells taken from anonymous donors and the firm says such treatments could be cheaper and easier to make and give to patients than existing therapies. CAR-T also wants to expand Allogene -T to more cancer types.